Skip to Main Content

A readout from the first late-stage clinical trial intended to treat the fatty liver disease known as NASH has delivered disappointing results.

Gilead Sciences said Monday that its experimental drug, called selonsertib, failed to improve liver scarring compared to a placebo in a Phase 3 clinical trial. The study enrolled nearly 900 patients with compensated cirrhosis, an advanced form of NASH at higher risk for liver-related death.


Shares of Gilead fell 4 percent on Monday night following the disclosure of the results. The setback is particularly discouraging because Gilead has invested heavily in a pipeline of NASH drugs, hoping clinical success will translate into new revenue and earnings growth.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.